Page 17 - C:\Users\Chris Patches\My ShareSync\Virtual Events\2024 - TMT Consumer\Book\Flip Output\

BioHarvest Sciences Inc.

SELECTED FINANCIAL ITEMS BHSC
(in millions of USD)
CQ2 '23 CQ3 '23 CQ4 '23 CQ1 '24 LTM
Income Statement Key Items
Total Revenue 2.75 3.24 4.52 5.34 15.85
Gross Profit 1.11 1.44 2.29 3.00 7.84
Gross Margin 40% 45% 51% 56% 49%
EBIT (2.88) (2.01) (2.55) (1.42) (8.86)
EBIT Margin -105% -62% -56% -27% -56%
Net Income to Common Shareholders (2.85) (1.73) (7.24) (6.58) (18.39)
Net Margin -104% -53% -160% -123% -116%

Balance Sheet Key Items
Total Assets 10.52 10.59 15.00 12.91 12.91
Cash & Short Term Investments 1.81 1.56 5.36 3.44 3.44
% of Assets 17% 15% 36% 27% 27%
Current Assets -Total 4.89 4.72 9.05 7.56 7.56
% of Assets 46% 45% 60% 59% 59%
Total Liabilities 16.68 18.34 29.86 16.10 16.10
% of Assets 159% 173% 199% 125% 125%
Current Liabilities - Total 12.89 14.60 26.47 13.32 13.32
% of Assets 123% 138% 176% 103% 103%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity (6.16) (7.75) (14.85) (3.18) (3.18)
% of Assets -59% -73% -99% -25% -25%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (2.88) (1.00) (2.99) (1.58) (8.45)
Net Cash Flow - Investing (0.37) (0.44) (0.29) (0.22) (1.32)
Net Cash Flow - Financing 4.75 1.18 7.01 (0.12) 12.82

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets Emerging Growth Consumer / Entertainment / Media Conference